Enterprise Value
11.99M
Cash
141.3M
Avg Qtr Burn
-21.58M
Short % of Float
8.20%
Insider Ownership
0.85%
Institutional Own.
68.64%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Mavorixafor (CXCR4 inhibitor) Details WHIM Syndrome | PDUFA Approval decision | |
Mavorixafor (CXCR4 inhibitor) Details Severe Congenital Neutropenia | Phase 2 Data readout | |
Mavorixafor (CXCR4 inhibitor) + ibrutinib Details Waldenstrom macroglobulinemia | Failed Discontinued | |
Mavorixafor (CXCR4 inhibitor) Details Renal cell carcinoma, Cancer | Failed Discontinued |